JP2005515172A - Ｈｃｖ阻害剤としての４−（６−員）−ヘテロアリールアシルピロリジン誘導体 - Google Patents

Ｈｃｖ阻害剤としての４−（６−員）−ヘテロアリールアシルピロリジン誘導体 Download PDF

Info

Publication number
JP2005515172A
JP2005515172A JP2003540176A JP2003540176A JP2005515172A JP 2005515172 A JP2005515172 A JP 2005515172A JP 2003540176 A JP2003540176 A JP 2003540176A JP 2003540176 A JP2003540176 A JP 2003540176A JP 2005515172 A JP2005515172 A JP 2005515172A
Authority
JP
Japan
Prior art keywords
tert
pyrrolidine
rel
carboxylic acid
isobutyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2003540176A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005515172A5 (https=
Inventor
ジャンパオロ・ブラヴィ
ロッセッラ・グイデッティ
デイビッド・ハイ
チャールズ・デイビッド・ハートリー
ピーター・デイビッド・ハウズ
デボラ・リネット・ジャクソン
ビクトリア・ルーシー・ヘレン・ラブグローブ
プリトム・シャー
マーティン・ジョン・スレイター
カトリーナ・ジェーン・ウェアリング
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0126440A external-priority patent/GB0126440D0/en
Priority claimed from GB0203900A external-priority patent/GB0203900D0/en
Priority claimed from GB0219321A external-priority patent/GB0219321D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of JP2005515172A publication Critical patent/JP2005515172A/ja
Publication of JP2005515172A5 publication Critical patent/JP2005515172A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2003540176A 2001-11-02 2002-10-30 Ｈｃｖ阻害剤としての４−（６−員）−ヘテロアリールアシルピロリジン誘導体 Ceased JP2005515172A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0126440A GB0126440D0 (en) 2001-11-02 2001-11-02 Compounds
GB0203900A GB0203900D0 (en) 2002-02-19 2002-02-19 Compounds
GB0219321A GB0219321D0 (en) 2002-08-19 2002-08-19 Compounds
PCT/EP2002/012176 WO2003037895A1 (en) 2001-11-02 2002-10-30 4-(6-membered)-heteroaryl acyl pyrrolidine derivatives as hcv inhibitors

Publications (2)

Publication Number Publication Date
JP2005515172A true JP2005515172A (ja) 2005-05-26
JP2005515172A5 JP2005515172A5 (https=) 2006-01-05

Family

ID=27256312

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003540176A Ceased JP2005515172A (ja) 2001-11-02 2002-10-30 Ｈｃｖ阻害剤としての４−（６−員）−ヘテロアリールアシルピロリジン誘導体

Country Status (9)

Country Link
US (1) US7259163B2 (https=)
EP (1) EP1440069B1 (https=)
JP (1) JP2005515172A (https=)
AR (1) AR037182A1 (https=)
AT (1) ATE370137T1 (https=)
DE (1) DE60221875T2 (https=)
ES (1) ES2289161T3 (https=)
TW (1) TW200302823A (https=)
WO (1) WO2003037895A1 (https=)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0211418D0 (en) * 2002-05-17 2002-06-26 Glaxo Group Ltd Compounds
JP4733023B2 (ja) 2003-04-16 2011-07-27 ブリストル−マイヤーズ スクイブ カンパニー Ｃ型肝炎ウイルスの大環状イソキノリンペプチド阻害剤
CN102911161A (zh) 2004-02-20 2013-02-06 贝林格尔.英格海姆国际有限公司 病毒聚合酶抑制剂
WO2005092863A1 (en) * 2004-03-26 2005-10-06 Smithkline Beecham Corporation 4-carbox pyrazole derivates useful as anti-viral agents
GB0423672D0 (en) * 2004-10-25 2004-11-24 Glaxo Group Ltd Compounds
GB0519485D0 (en) * 2005-09-23 2005-11-02 Glaxo Group Ltd Compounds
WO2007039146A1 (en) * 2005-09-23 2007-04-12 Smithkline Beecham Corporation 4-carboxy pyrazole derivatives as anti-viral agents
GB0519478D0 (en) * 2005-09-23 2005-11-02 Glaxo Group Ltd Compounds
GB0519486D0 (en) * 2005-09-23 2005-11-02 Glaxo Group Ltd Compounds
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
US20090004140A1 (en) * 2007-06-26 2009-01-01 Yao-Ling Qiu 4-substituted pyrrolidine as anti-infectives
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
WO2010065674A1 (en) 2008-12-03 2010-06-10 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
CA2750577A1 (en) 2008-12-03 2010-06-10 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
NZ593649A (en) 2008-12-23 2013-11-29 Gilead Pharmasset Llc Nucleoside analogs
AU2009329872B2 (en) 2008-12-23 2016-07-07 Gilead Pharmasset Llc Synthesis of purine nucleosides
PA8855601A1 (es) 2008-12-23 2010-07-27 Forformidatos de nucleósidos
SG174883A1 (en) 2009-03-27 2011-11-28 Presidio Pharmaceuticals Inc Fused ring inhibitors of hepatitis c
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
CN102812003B (zh) 2009-12-18 2015-01-21 欧洲筛选有限公司 吡咯烷羧酸衍生物、药物组合物以及在代谢紊乱中作为g-蛋白偶联受体43(gpr43)激动剂使用的方法
UY33310A (es) 2010-03-31 2011-10-31 Pharmasset Inc Sintesis estereoselectiva de activos que contienen fosforo
SG184324A1 (en) 2010-03-31 2012-11-29 Gilead Pharmasset Llc Nucleoside phosphoramidates
WO2011149856A1 (en) 2010-05-24 2011-12-01 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
AR082619A1 (es) 2010-08-13 2012-12-19 Hoffmann La Roche Inhibidores del virus de la hepatitis c
SG189985A1 (en) 2010-10-26 2013-06-28 Presidio Pharmaceuticals Inc Inhibitors of hepatitis c virus
CA2818853A1 (en) 2010-11-30 2012-06-07 Gilead Pharmasset Llc 2'-spirocyclo-nucleosides for use in therapy of hcv or dengue virus
WO2012123298A1 (en) 2011-03-11 2012-09-20 F. Hoffmann-La Roche Ag Antiviral compounds
US20120328565A1 (en) 2011-06-24 2012-12-27 Brinkman John A Antiviral compounds
EP2709613B2 (en) 2011-09-16 2020-08-12 Gilead Pharmasset LLC Methods for treating hcv
RU2014117587A (ru) 2011-10-10 2015-11-20 Ф. Хоффманн-Ля Рош Аг Противовирусные соединения
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
KR20140104030A (ko) 2011-12-16 2014-08-27 에프. 호프만-라 로슈 아게 Hcv ns5a의 억제제
MX350810B (es) 2011-12-20 2017-09-20 Riboscience Llc Derivados de los nucleosidos sustituidos en 4 '-azido, 3 '-fluoro como inhibidores de la replicacion del rna del vhc.
AU2012357940B2 (en) 2011-12-20 2017-02-16 Riboscience Llc 2',4'-difluoro-2'-methyl substituted nucleoside derivatives as inhibitors of HCV RNA replication
JP6092261B2 (ja) 2012-02-24 2017-03-08 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 抗ウイルス化合物
US20140010783A1 (en) 2012-07-06 2014-01-09 Hoffmann-La Roche Inc. Antiviral compounds
CN105073726B (zh) 2013-01-23 2017-05-31 弗·哈夫曼-拉罗切有限公司 抗病毒三唑衍生物
EP2950786B1 (en) 2013-01-31 2019-11-27 Gilead Pharmasset LLC Combination formulation of two antiviral compounds
BR112015021429A2 (pt) 2013-03-05 2017-07-18 Hoffmann La Roche compostos antivirais
MA38678A1 (fr) 2013-05-16 2017-07-31 Riboscience Llc Dérivés nucléosidiques 4'-azido, 3'désoxy-3'-fluoro substitués
US20180200280A1 (en) 2013-05-16 2018-07-19 Riboscience Llc 4'-Fluoro-2'-Methyl Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication
JP6366693B2 (ja) 2013-05-16 2018-08-01 リボサイエンス・エルエルシー ４’−フルオロ−２’−メチル置換ヌクレオシド誘導体
PT3038601T (pt) 2013-08-27 2020-06-30 Gilead Pharmasset Llc Formulação combinada de dois compostos antivirais
CN105916500A (zh) 2013-11-27 2016-08-31 欧洲筛选有限公司 用于治疗炎性疾病的化合物、药物组合物和方法
AU2018335411B2 (en) 2017-09-21 2024-06-27 Riboscience Llc 4'-fluoro-2'-methyl substituted nucleoside derivatives as inhibitors of HCV RNA replication
CN109678814B (zh) * 2018-12-28 2021-03-23 浙江外国语学院 一种制备2-氯-1, 3-噻唑-5-甲醛的方法
US11345681B1 (en) 2020-06-05 2022-05-31 Kinnate Biopharma Inc. Inhibitors of fibroblast growth factor receptor kinases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT395007B (de) * 1990-03-29 1992-08-25 Noe Christian Modifizierte cyclische aminosaeuren und aus diesen synthetisierte dipeptide und verfahren zu ihrer herstellung
AU3761393A (en) * 1992-03-20 1993-10-21 Wellcome Foundation Limited, The Indole derivatives with antiviral activity
CN1328546A (zh) * 1998-04-23 2001-12-26 艾博特公司 作为神经氨酸酶抑制剂的吡咯烷
US6455571B1 (en) * 1998-04-23 2002-09-24 Abbott Laboratories Inhibitors of neuraminidases

Also Published As

Publication number Publication date
AR037182A1 (es) 2004-10-27
ES2289161T3 (es) 2008-02-01
US7259163B2 (en) 2007-08-21
DE60221875T2 (de) 2007-12-20
TW200302823A (en) 2003-08-16
EP1440069A1 (en) 2004-07-28
DE60221875D1 (de) 2007-09-27
ATE370137T1 (de) 2007-09-15
WO2003037895A1 (en) 2003-05-08
EP1440069B1 (en) 2007-08-15
US20050043390A1 (en) 2005-02-24

Similar Documents

Publication Publication Date Title
US7259163B2 (en) 4-(6-membered)-heteroaryl acyl pyrrolidine derivatives as HCV inhibitors
US7304087B2 (en) 1-acyl-pyrrolidine derivatives for the treatment of viral infections
EP1301487B1 (en) Viral polymerase inhibitors
US6841566B2 (en) Viral polymerase inhibitors
US20050043545A1 (en) 4-(5-Membered)-heteroaryl acyl pyrrolidine derivatives as hcv inhibitors
CA2460512A1 (en) Thiazolidine derivatives and medicinal use thereof
JP2005511572A (ja) Ｈｃｖ阻害剤としてのアシルジヒドロピロール誘導体
JP2010510191A (ja) 抗ウイルス剤としての２−カルボキシチオフェン誘導体
ZA200504893B (en) Viral polymerase inhibitors
JP2008517968A (ja) Ｃ型肝炎ウイルス阻害薬としての４−メトキシメチル−ピロリジン−２−カルボン酸化合物およびその誘導体
JP2007533693A (ja) Ｈｃｖ阻害剤としてのアシルジヒドロピロール誘導体
WO2007039145A1 (en) C (2) -heteroarylmethyl-c (4) -pyrazinyl-2-yl acyl pyrrolidine compounds and their use for treating viral infections, especially hepatitis c virus
JP2005530802A (ja) ピロールのアシル二環式誘導体
JP2008517969A (ja) Ｃ型肝炎ウイルス阻害薬としての４−（ピラジン−２−イル）−ピロリジン−２−カルボン酸化合物およびその誘導体
WO2004009543A2 (en) 1-carbonyl-4-cyano-pyrrolidine-2-carboxylic acid derivatives as hepatitis c virus inhibitors
WO2004076415A1 (en) 1- (hetero)aroyl-pyrrolidine-2-carboxylic acid derivatives useful as anti.viral agents
WO2004060889A1 (en) 5-thiazole substituted 2-pyrrolidine-carboxylic acids
WO2007039143A1 (en) C (2) -heteroarylmethyl-c (4) -pyrazin-2-yl acyl pyrrolidine compounds and their user for treating viral infections, especially hepatitics c (hcv)
ZA200502945B (en) 1-Acyl-pyrrolidine derivatives for the treatment of viral infections.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051020

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20051020

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090616

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090907

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20091006

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20100223